Literature DB >> 23962626

Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus.

Luca Quartuccio1, Maurizio Rupolo, Mariagrazia Michieli, Salvatore De Vita.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23962626     DOI： 10.1093/rheumatology/ket284

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  4 in total

1.  Emerging therapies targeting the ubiquitin proteasome system in cancer.

Authors:  Nathaniel M Weathington; Rama K Mallampalli
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

Review 2.  Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications.

Authors:  Natasha Jordan; David D'Cruz
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-12       Impact factor: 5.346

Review 3.  Haematological manifestations of lupus.

Authors:  Anum Fayyaz; Ann Igoe; Biji T Kurien; Debashish Danda; Judith A James; Haraldine A Stafford; R Hal Scofield
Journal:  Lupus Sci Med       Date:  2015-03-03

4.  Pharmacodynamic monitoring of (immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis.

Authors:  Karina A de Groot; Michel Tsang A Sjoe; Denise Niewerth; Jacqueline Cloos; Jonathan L Blank; Hans W M Niessen; Sonja Zweegman; Alexandre E Voskuyl; Gerrit Jansen; Joost W van der Heijden
Journal:  Lupus Sci Med       Date:  2015-12-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.